Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-blind, Parallel-group Trial to Evaluate the Lot Consistency, Immunogenicity, and Safety of AV7909 for Postexposure Prophylaxis of Anthrax in Healthy Adults

NCT03877926 is registered in ClinicalTrials.gov with Emergent BioSolutions as lead sponsor.

NCT NCT03877926
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03877926 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-blind, Parallel-group Trial to Evaluate the Lot Consistency, Immunogenicity, and Safety of AV7909 for Postexposure Prophylaxis of Anthrax in Healthy Adults
Lead sponsor
Emergent BioSolutions
Phase
Phase 3
Overall status
Completed
Start date
March 11, 2019
Completion date
August 6, 2020
Enrollment
3,689 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

anthrax